Stock Watch: Competitive Wrinkles Mar KalVista, Vertex, Ironwood Trial Successes
Once Started, Clinical Development Is Difficult To Stop
Executive Summary
It is not ideal to miss the emergence of competition that could reduce your market. Even worse is not to find out that your drug is inferior to generic competition until the end of Phase III.